Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

FXR, a multipurpose nuclear receptor.

Florence Y Lee1, Hans Lee, Melissa L Hubbert

  • 1Department of Biological Chemistry, University of California at Los Angeles, Los Angeles, CA 90095, USA.

Trends in Biochemical Sciences
|August 16, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Surufatinib plus toripalimab for patients with advanced solid tumors and disease progression after prior immunotherapy: an open-label multi-cohort phase 2 trial.

Cancer immunology, immunotherapy : CII·2026
Same author

Anti-PD-1 monoclonal antibody suppresses hepatitis B virus in patients with hepatocellular carcinoma.

Chinese medical journal·2026
Same author

Real-World Treatment Patterns, HER2 Testing Practices, and Clinical Outcomes in HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer.

Advances in therapy·2026
Same author

Root Cause Determination for Customer Complaint Biopharmaceutical Drug Product Samples with Abnormal Appearance.

PDA journal of pharmaceutical science and technology·2026
Same author

AdvanTIG-206: a phase II, randomized study of ociperlimab plus tislelizumab and BAT1706 (bevacizumab biosimilar) versus tislelizumab and BAT1706 in first-line hepatocellular carcinoma.

Cancer immunology, immunotherapy : CII·2026
Same author

Hepatic SEC16B regulates lipid homeostasis by coordinating VLDL secretion and lipid droplet expansion.

The Journal of clinical investigation·2026
Same journal

Peptideins: Navigating the gray zone of the proteome.

Trends in biochemical sciences·2026
Same journal

A metabolon channels nicotine biosynthesis.

Trends in biochemical sciences·2026
Same journal

Better call chaperone.

Trends in biochemical sciences·2026
Same journal

Biochemistry at scale: Seeing both the forest and the trees.

Trends in biochemical sciences·2026
Same journal

Voices across Asia and Oceania: Biochemistry across borders.

Trends in biochemical sciences·2026
Same journal

Metabolic control of RNA splicing by polyamines.

Trends in biochemical sciences·2026
See all related articles

The farnesoid X receptor (FXR) regulates key metabolic processes. Targeting FXR with agonists may offer new treatments for diabetes, gallstones, and liver or intestinal toxicity.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Endocrinology

Background:

  • The farnesoid X receptor (FXR) is a nuclear receptor superfamily member.
  • FXR acts as a ligand-activated transcription factor.
  • Recent research highlights FXR's significant functional importance.

Purpose of the Study:

  • To review the crucial roles of FXR.
  • To explore the therapeutic potential of FXR modulation.

Main Methods:

  • Literature review of recent studies on FXR.
  • Analysis of FXR's involvement in metabolic pathways.
  • Evaluation of FXR's role in physiological and toxicological responses.

Main Results:

  • FXR is critical for bile acid homeostasis.

Related Experiment Videos

  • FXR influences lipoprotein and glucose metabolism.
  • FXR plays a role in hepatic regeneration, gut microbiota, and toxin response.

    • Conclusions:

    • FXR agonists show therapeutic promise.
    • Potential applications include treating diabetes, gallstones, and liver/intestinal toxicities.